<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04999176</url>
  </required_header>
  <id_info>
    <org_study_id>VALERIA TRIAL</org_study_id>
    <nct_id>NCT04999176</nct_id>
  </id_info>
  <brief_title>Venous Thromboembolism Prophylaxis After Gynecological Pelvic Cancer Surgery With Rivaroxaban vs Enoxaparin</brief_title>
  <acronym>VALERIA</acronym>
  <official_title>A Multicenter, Open-label, Prospective, Randomized, Active-controlled Study on the Efficacy and Safety of Oral Rivaroxaban Versus Enoxaparin for Venous Thromboembolism Prophylaxis After Major Gynecological Cancer Surgery.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>André Luiz Malavasi Longo de Oliveira</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science Valley Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Science Valley Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Valeria trial will provide high-quality evidence regarding the efficacy and safety of&#xD;
      oral rivaroxaban in thromboprophylaxis after gynecological pelvic cancer surgery in&#xD;
      comparison with standard parenteral enoxaparin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cancer-associated thrombosis is the second leading cause of mortality in cancer patients,&#xD;
      mainly due to the most common complication, venous thromboembolism (VTE). New oral&#xD;
      antithrombotic strategies for VTE prevention after gynecological cancer surgery might be&#xD;
      non-inferior to parenteral low-molecular-weight heparin (LMWH) in efficacy and safety with&#xD;
      increased adherence, comfort, and reduced costs.&#xD;
&#xD;
      This is a multicenter, open-label, prospective, randomized, active-controlled study, and&#xD;
      non-inferiority trial. Four hundred and forty patients submitted to major gynecological&#xD;
      cancer surgery will be randomized in a 1:1 ratio to receive either oral rivaroxaban 10 mg&#xD;
      once daily or subcutaneous enoxaparin 40mg once daily for 30 days post-operative. The primary&#xD;
      efficacy outcome is a combination of symptomatic VTE and VTE-related death or VTE detected by&#xD;
      mandatory Doppler ultrasound on day 30±4 post-operative. The primary safety outcome is the&#xD;
      incidence of major and clinically relevant non-major bleeding according to the International&#xD;
      Society on Thrombosis and Hemostasis criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2020</start_date>
  <completion_date type="Anticipated">July 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This study aims to evaluate the efficacy and safety of oral rivaroxaban 10 mg for 30 days in thromboprophylaxis after gynecological pelvic cancer surgery compared to subcutaneous enoxaparin 40 mg. The primary efficacy outcome is a combination of symptomatic VTE and VTE-related death or VTE detected by mandatory Doppler ultrasound on day 30±4 post-operative. The primary safety outcome is the incidence of major and clinically relevant non-major bleeding according to ISTH criteria.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Venous thromboembolism and VTE related-death</measure>
    <time_frame>At day 30 +/- post hospital discharge</time_frame>
    <description>A composite of symptomatic objectively confirmed VTE (deep venous thrombosis, pulmonary embolism, and asymptomatic ultrasonography-confirmed, deep venous thrombosis or venous thromboembolism-related death at 30 days post-operative.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinically relevant bleeding</measure>
    <time_frame>At day 30 +/- post hospital discharge</time_frame>
    <description>A combination of major bleeding plus clinically relevant non-major bleeding at 30 days post-operative.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>A composite of myocardial infarction, stroke, arrhythmias, heart failure, venous thromboembolism (VTE), and all-cause death</measure>
    <time_frame>At day 30 +/- post hospital discharge</time_frame>
    <description>A composite of myocardial infarction, stroke, arrhythmias, heart failure, venous thromboembolism (VTE), and all-cause death.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Cancer</condition>
  <condition>Rivaroxaban</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Thromboprophylaxis</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Rivaroxaban (10 mg once daily) for 30 days post-operative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous Enoxaparin (40 mg once daily) for 30 days post-operative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with oral rivaroxaban (10 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.</description>
    <arm_group_label>Rivaroxaban</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Patients will be submitted to an initial screening evaluation during hospitalization. At discharge, they will be randomized and enrolled to be treated with subcutaneous enoxaparin (40 mg once daily, for 30 days), once randomized to this group. A mandatory lower limb Doppler ultrasound will be carried out on day 30±4 as part of the primary efficacy endpoint. A final follow-up phone call visit will be performed on day 60 postoperative.</description>
    <arm_group_label>Enoxaparin</arm_group_label>
    <other_name>Clexane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female patients 18 years of age or older&#xD;
&#xD;
          -  Have undergone major gynecological cancer surgery (staging surgery, debulking surgery,&#xD;
             -&#xD;
&#xD;
          -  Total or radical hysterectomy, unilateral or bilateral salpingo-oophorectomy,&#xD;
             omentectomy, lymph node removal, open or laparoscopic access)&#xD;
&#xD;
          -  Have signed informed consent&#xD;
&#xD;
          -  Have received thromboprophylaxis with low-molecular-weight heparin, fondaparinux, or&#xD;
             unfractionated heparin during the index hospitalization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Refusal of informed consent&#xD;
&#xD;
          -  Physician decision that involvement in the trial was not in the patient's best&#xD;
             interest&#xD;
&#xD;
          -  Patients with a medical indication for anticoagulation therapy at the time of&#xD;
             inclusion (for example, diagnosis of venous thromboembolism, atrial fibrillation,&#xD;
             mechanical valve prosthesis)&#xD;
&#xD;
          -  Patients with contraindications to anticoagulation (active bleeding, liver failure,&#xD;
             blood dyscrasia, or prohibitive hemorrhagic risk in the investigator's assessment)&#xD;
&#xD;
          -  Active cancer (excluding non-melanoma skin cancer) defined as cancer not in remission&#xD;
             or radiotherapy requiring active chemotherapy or adjunctive therapies such as&#xD;
             immunotherapy&#xD;
&#xD;
          -  Use of strong inhibitors of cytochrome P450 (CYP) 3A4 and/or glycoprotein P (P-gp)&#xD;
             (eg, protease inhibitors, ketoconazole, Itraconazole) and/or use of P-gp and strong&#xD;
             inducers of CYP3A4 (how but not limiting rifampicin/rifampicin, rifabutin,&#xD;
             rifapentine, phenytoin, phenobarbital, carbamazepine or St. John's wort)&#xD;
&#xD;
          -  Creatinine clearance &lt;30 ml / min&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Known HIV infection&#xD;
&#xD;
          -  Presence of one of the following uncontrolled or unstable cardiovascular diseases:&#xD;
             stroke, ECG confirmed acute ischemia or myocardial infarction, and/or clinically&#xD;
             significant dysrhythmia&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduardo Ramacciotti, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Science Valley Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>André Luiz Oliveira, MD</last_name>
    <phone>+5508005917817</phone>
    <email>drandreluiz@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leandro Agati, PhD</last_name>
    <phone>+551144688183</phone>
    <email>agati@svriglobal.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Science Valley Research Institute</name>
      <address>
        <city>Santo André</city>
        <state>São Paulo</state>
        <zip>09030370</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Ohashi Y, Ikeda M, Kunitoh H, Sasako M, Okusaka T, Mukai H, Fujiwara K, Nakamura M, Kimura T, Ibusuki K, Sakon M. Venous thromboembolism in patients with cancer: design and rationale of a multicentre, prospective registry (Cancer-VTE Registry). BMJ Open. 2018 May 30;8(5):e018910. doi: 10.1136/bmjopen-2017-018910.</citation>
    <PMID>29848769</PMID>
  </reference>
  <reference>
    <citation>Comerota AJ, Ramacciotti E. A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. Am J Med Sci. 2016 Jul;352(1):92-106. doi: 10.1016/j.amjms.2016.03.018. Epub 2016 Apr 6. Review.</citation>
    <PMID>27432042</PMID>
  </reference>
  <reference>
    <citation>Guntupalli SR, Brennecke A, Behbakht K, Tayebnejad A, Breed CA, Babayan LM, Cheng G, Ramzan AA, Wheeler LJ, Corr BR, Lefkowits C, Sheeder J, Matsuo K, Flink D. Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm: A Randomized Clinical Trial. JAMA Netw Open. 2020 Jun 1;3(6):e207410. doi: 10.1001/jamanetworkopen.2020.7410.</citation>
    <PMID>32589230</PMID>
  </reference>
  <reference>
    <citation>Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Francis CW, Gates LE, Kakkar AK, Levine MN, Liebman HA, Tempero MA, Lyman GH, Falanga A. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020 Feb 10;38(5):496-520. doi: 10.1200/JCO.19.01461. Epub 2019 Aug 5.</citation>
    <PMID>31381464</PMID>
  </reference>
  <reference>
    <citation>Chan NC, Weitz JI. Rivaroxaban for prevention and treatment of venous thromboembolism. Future Cardiol. 2019 Mar;15(2):63-77. doi: 10.2217/fca-2018-0076. Epub 2019 Feb 19. Review.</citation>
    <PMID>30779598</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Science Valley Research Institute</investigator_affiliation>
    <investigator_full_name>André Luiz Malavasi Longo de Oliveira</investigator_full_name>
    <investigator_title>Clinical Director - São Paulo State Public Women's Health Reference Center</investigator_title>
  </responsible_party>
  <keyword>Direct oral anticoagulants</keyword>
  <keyword>Gynecologic cancer</keyword>
  <keyword>Low-molecular weight heparin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

